Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eva Wolf

Internal Medicine Greenville, SC Medical Doctor

NPI 1437578069 CMS profile 2781561

50 Cross Park Ct, Greenville, SC 29605

Open in the dashboard

General payments

$3,317

141 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eva Wolf of Greenville, SC is reported in the CMS Open Payments database as having received $3,317 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,132 44
2024 General $1,042 41
2023 General $624 30
2022 General $58 3
2021 General $270 9
2020 General $59 4
2019 General $133 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eva Wolf
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Eva Wolf were reported at $1,132. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Eva Wolf Internal Medicine median Middle half National median
2019 $133 $159 $48–$570 $163
2020 $59 $119 $33–$402 $114
2021 $270 $135 $37–$521 $132
2022 $58 $141 $42–$496 $149
2023 $624 $149 $45–$519 $160
2024 $1,042 $154 $47–$537 $164
2025 $1,132 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,203 49 payments
  2. Lilly USA, LLC $698 31 payments
  3. Abbott Laboratories $301 19 payments
  4. Pfizer Inc. $180 4 payments
  5. W. L. Gore & Associates, Inc. $162 1 payment
  6. Exact Sciences Corporation $151 10 payments
  7. GlaxoSmithKline, LLC. $140 4 payments
  8. Dexcom, Inc. $70 4 payments
  9. Inspire Medical Systems, Inc. $67 1 payment
  10. Merck Sharp & Dohme Corporation $49 2 payments
  11. Other $295 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,317 141 payments
Products named General payments · program years 2019–2025
  1. ZEPBOUND $420 14 payments
  2. Wegovy $364 14 payments
  3. MOUNJARO $277 18 payments
  4. FreeStyle Libre 3 $243 13 payments
  5. Ozempic $199 11 payments
  6. RYBELSUS $184 10 payments
  7. Tresiba $164 9 payments
  8. GORE SYNECOR Preperitoneal Biomaterial $162 1 payment
  9. ABRYSVO $124 1 payment
  10. Cologuard Collection Kit $94 6 payments
  11. Other $1,146 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 139 drugs

Part D claims

8,480

Median for Internal Medicine: 777

Drug cost

$819,850

Median for Internal Medicine: $73,373

Branded share of claims

19.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 127 $225,284
Eliquis Apixaban Brand 85 $87,515
Mounjaro Tirzepatide Brand 50 $71,120
Jardiance Empagliflozin Brand 46 $64,140
Linzess Linaclotide Brand 41 $40,682
Rybelsus Semaglutide Brand 20 $38,060
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $36,129
Tresiba Flextouch U-200 Insulin Degludec Brand 25 $32,175
Trulicity Dulaglutide Brand 13 $23,270
Januvia Sitagliptin Phosphate Brand 23 $23,242

The 10 drugs with the highest cost, of 139 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$161,412

Of which drugs: $8,942

Medicare patients

303

Average age 73

Services billed

3,419

238 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 48%
Diabetes 34%
Depression 27%
Osteoporosis 25%
Ischemic heart disease 23%
Chronic kidney disease 18%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 16 16 $4,344
Vaccine for influenza for injection into muscle 90662 Office 50 50 $4,091

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $191
$191 — —
MOUNJARO
  • Lilly USA, LLC $133
$133 50 —
ABRYSVO
  • PFIZER INC. $124
$124 — —
AREXVY
  • GlaxoSmithKline, LLC. $92
$92 — —
Veozah
  • Astellas Pharma US Inc $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record